Stephens & Co. Maintains Overweight on Vericel, Raises Price Target to $42

Benzinga · 05/11/2023 11:10
Stephens & Co. analyst Chris Cooley maintains Vericel (NASDAQ:VCEL) with a Overweight and raises the price target from $39 to $42.